AI-enabled data driven insights to drive novel biomarker discovery, improve clinical trial performance and gain access to high-quality real world genomic + radiomic + clinical data. Global. Decentralized. Platform Agnostic.The SOPHiA DDM™ platform's data and predictive analytics capabilities leverage proprietary algorithms powering smart diagnostics and multimodal approaches to better inform treatment decisions, therapy selection and response, patient journey, resistance mechanism, and real-world practices.My remit is to build a world-class business unit that builds on the DDM™ platform's data and analytics to drive key partnerships across the drug-development ecosystem to advance novel therapies. From sales & marketing to strategy & business operations, the BioPharma BU delivers high-impact, business-critical results and is a growth driver for the company and its shareholders.

Lead the Commercial strategies for new corporate initiatives, including companion diagnostics/single-site IVD, New SaaS Analytics product & Go To Market (CellEngine), Big Data, Multiomics & AI/MLPart of the M&A Deal Team for corporate development, due diligence, new technology evaluations, licensing, strategic partnerships

Drive the build-out and strategy of new Tempus Life Sciences ALPHA business unit in order to maximize customer return across the value chain. Nurture Strategic Partnerships, monetize Tempus assets and IP and promote market penetration through innovative deal structuring and negotiations, asset and portfolio valuation, risk analysis and financial modeling to ultimately drive revenue

Making precision medicine a reality by leveraging machine learning/AI to gather, structure and analyze clinical and molecular data at scale. We create proprietary data sets for analyses across a wide variety of patient cohorts...enabling translational research, better trial design, patient recruitment, treatment-response and outcomes data, and FDA-grade synthetic control armsOur genomic tests interrogate matched tumor/normal DNA, as well as whole transcriptome RNA to understand both a patient's clinical and molecular profile at a deeper level so we can help identify tailored treatment options, along with key immunotherapy markers of interest and their correlation to outcomes, leveraging the power of pooled and aggregate data.Real World Evidence for the Precision Medicine era.

Drive continued growth of the Pharma Services division through strategic evaluations of new market opportunities, potential acquisitions , new technology evaluation, competitive market analysis and strategic partnershipsSupport overall growth strategy through end-to-end research, analysis, modeling and presentation delivery of M&A targetsContinue to drive global strategic business expansion/collaboration opportunities with Big Pharma/IVD/Healthcare & Government institutionsAnalyze competitive landscape and internal gap analyses to determine trends and identify growth opportunities spanning new markets, product development and collaborationsLead down-selection and due-diligence of strategic OEM/partner opportunities in support of CDx initiatives Ability to prospect, target, advance, negotiate and close corporate and business development activities, supporting both organic and inorganic growth

Sr Director, Strategic Sales within Covance Central Labs, a division of LabCorp. Supporting Esoteric/Specialty Testing, Vaccines, Translational Biomarkers and Companion Diagnostics.Support CDx through all phases of development to commercial launch, including IVD & LDT development and clinical trials testing support through to PMA/510KGenomics Services (Next-Gen Sequencing, DNA-seq, RNA-seq, miRNA/mRNA profiling, gene expression, Copy Number Variance, etc)Monogram Biosciences (infectious diseases, viral resistance, Immuno-oncology, viral neutralization)Center for Molecular Biology and Pathology (IHC, mutational analysis, Next Gen Sequencing, Cytogenetics, Anatomic Pathology, etc)Flow Cytometry (method development, custom immunophenotyping and global deployment)Pharmacodynamic markers across all therapeutic areasVaccine & Immunotherapeutic biomarker support

Key Account Director, Strategic Sales within LabCorp Clinical Trials division, supporting Central Lab, Esoteric/Specialty Testing, Translational Biomarkers and Companion Diagnostics.Labcorp Genomics Services (Next-Gen Sequencing, DNA-seq, RNA-seq, miRNA profiling, gene expression, translational Biomarkers and liquid biopsy CTC)Monogram Biosciences (infectious diseases, viral resistance, Immuno-oncology, viral neutralization)Center for Molecular Biology and Pathology (IHC, mutational analysis, Next Gen Sequencing, Cytogenetics, Anatomic Pathology, etc)Flow Cytometry (method development, custom immunophenotyping and global deployment)Pharmacodynamic markers across all therapeutic areasSupport CDx through all phases of development to commercial launch, including LDT development and clinical trials testing support through to PMA/510K

Strategic partner for vaccines and bioanalytical assay development, clinical testing services and post-approval expertise to support pharmaceutical, vaccines and biologics commercialization efforts. Identify, target and develop opportunistic leads, extend product reach, professionally present capabilities, manage the sales process through close and handle all aspects of contract negotiations.Supported the strategic development, diversification and growth of the Vaccines & Biologics Lab, following our divestiture from the Merck Vaccines Division and acquisition by PPD, Inc. Responsible for all new and existing business, including Executive Leadership Team responsible for sales, product commercialization, strategic collaborations and new technology development.Current clients and strategic partners include representatives from various international healthcare stakeholders spanning pharmaceutical/biotech, government, public health, non-government and academia.

Program Management Group, responsible for the development, optimization and validation of vaccine immunoassays used as primary efficacy biomarkers in support of several Phase II/III viral and bacterial programs. Experience in cell-based and multiplexed (Flow, Luminex) assay development and clinical testing. Major focus on FACS-based, total IgG and functional opsonophagoctyic assay development to support a high-priority Phase II bacterial vaccine program.

Master's Thesis: Monitoring the Role of Tissue Factor, Cholesterol and the Fcgamma Receptor in Arteriosclerosis/Thrombosis & Vascular Biology.Cholesterol Enrichment of Human Monocyte/Macrophages Induces Surface Exposure of Phosphatidylserine and the Release of Biologically-Active Tissue Factor Microvesicles. Arterioscler Thromb Vasc Biol 2007;27;430-435;